NCT06171113View on ClinicalTrials.gov

A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

December 12, 2023

Primary Completion Date

August 14, 2025

Study Completion Date

August 14, 2025

Conditions
Malaria, Falciparum
Interventions
DRUG

GSK4024484C

Doses administrated orally with 240 mL of water.

DRUG

Placebo

Doses administrated orally with 240 mL of water.

Trial Locations (1)

Unknown

RECRUITING

Clinical Unit Cambridge (Cuc)-Cambridge-United Kingdom-C, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
collaborator

Medicines for Malaria Venture

OTHER

lead

GlaxoSmithKline

INDUSTRY

NCT06171113 - A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants | Biotech Hunter | Biotech Hunter